RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
Vous n'êtes pas connecté
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to […]
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
SAN DIEGO, Sept. 12, 2024. Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound...
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy...
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy...
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage...
Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...